Introduction
With the recent advent of gene therapy in orthopedic research, there has been an increasing number of studies harnessing recombinant adenoviral vectors for the development of systems enhancing and/or inducing bone formation. [1] [2] [3] [4] [5] [6] [7] [8] Localized delivery of cells transduced ex vivo with adenoviral vectors encoding bone morphogenetic proteins (BMPs) has proven successful in induction of new bone formation in hetero-and orthotopic locations. Although safe and efficacious gene-based bone induction systems have yet to be developed, the adenoviral delivery of BMP offers the potential of rapidly achieving local effective concentrations of the protein to induce bone formation. These systems circumvent the need for releasing carriers and overcome specific BMP lability upon processing, sterilization, and storage.
The optimal cell type for the ex vivo adenoviral BMP gene delivery remains undetermined, although specific requirements for the target cell can be identified. The cell types suitable for ex vivo adenoviral transduction should be readily accessible, available in a sufficient number or able to be expanded in culture. The target cells should demonstrate a high rate of transduction with the adenovirus vector, which results in efficient transgene expression. The engraftment rate of the cells transduced by adenovirus should be adequate to elicit sufficient production of BMP in vivo.
Systems utilizing various cell types transduced ex vivo with adenovirus type 5 (Ad5) encoding BMP2 (Ad5-BMP2) have been employed as a means for osteoinduction. Recently, the concept of utilizing bone cell precursors for adenoviral BMP2-induced bone formation has been instituted with the premise of harnessing the osteogenic potential of these cells, thereby achieving more efficient bone formation. In addition to expressing BMP2, such cells may directly participate in bone formation as targets of BMP2 activity. 9 Specific cell types with various osteogenic potentials have been examined by Musgrave et al 10 for their ability to form heterotopic bone following ex vivo transduction with Ad5-BMP2. Among the cells studied, primary mesenchymal stem cells (MSCs) and primary articular chondrocytes did not induce bone detectable radiographically, whereas primary muscle-derived cells were capable of forming bone in vivo. In this study, the term 'osteocompetence' was coined referring to the cells' responsiveness to in vitro BMP2 stimulation, which determines the effectiveness of the cell in Ad5-BMP2-mediated osteoinduction in vivo.
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In another study, Gazit et al 9 demonstrated in vitro the ability of MSCs engineered to produce BMP2 to undergo osteoblastic differentiation. In vivo, these cells enhanced the regeneration of bone defects via autocrine and paracrine mechanisms and also integrated into the newly formed bone.
Recently, we have described, a novel recombinant chimeric adenoviral BMP2 vector, 11, 12 which consists of Ad5 containing a fiber gene of adenovirus type 35 (Ad5F35-BMP2). Comparison of Ad5F35-BMP2 with Ad5-BMP2 demonstrated the ability of the former to elicit significantly higher expression of BMP2 in vitro in human bone marrow MSCs (BM-MSCs). Using nonobese diabetic severe immunodeficiency (NOD/SCID) mice, BM-MSCs transduced with Ad5F35-BMP2 demonstrated significantly greater potential to induce heterotopic bone formation than the same cells transduced with Ad5-BMP2. 11, 12 We have previously demonstrated 12 by FACS analysis with a monoclonal antibody against the Coxsackie-adenovirus receptor (CAR) that human BM-MSCs are deficient in CAR that is a prerequisite for transduction with Ad5-BMP2, whereas Ad5F35-BMP2 transduces cells in a CAR-independent fashion.
In order to establish the most efficacious system for adenoviral BMP2 delivery, the objectives of the present study were to analyze and compare the abilities of various human cell types with inherently dissimilar osteogenic potentials to induce heterotopic bone formation in vivo following ex vivo transduction with Ad5-BMP2 or Ad5F35-BMP2 representing low-and high BMP2 expression, respectively.
Materials and methods

Cells
Human embryonic kidney (293) and diploid human fetal lung (MRC-5) cell lines were obtained from American Type Culture Collection (Manassas, VA, USA). Human skin fibroblasts (SFs) were a generous gift from Dr Cliona Rooney (Baylor College of Medicine, TX, USA). The cell types were propagated in Dulbecco's modified eagles medium (DMEM; Biowhittaker, Walkersville, MD, USA), supplemented with 10% fetal bovine serum (FBS; Hyclone, Logan, UT, USA), 100 mg/ml penicillin-streptomycin, and 0.25 mg/ml amphotericin B (Life Technologies, Gaithersburg, MD, USA), and grown in a humid chamber at 371C and 5% CO 2 . BM-MSCs were derived from discarded human bone marrow from healthy donors as previously described. 11, 12 Cells were isolated by gradient density centrifugation on Ficoll-Paquet PLUS (Amersham Pharmacia Biotech, Piscataway, NJ, USA), plated at 5 Â 10 6 cells/cm 2 in the medium above, and enzymatically collected before becoming confluent. 13 
Construction of adenoviral vectors
A replication-defective human Ad5 containing a cDNA for BMP2 in the E1 region of the virus (Ad5-BMP2) was constructed by in vivo homologous recombination in 293 cells as previously described.
14 A replication-defective human Ad5 with an adenovirus type 35 fiber, which also contains a cDNA for BMP2 in the E1 region (Ad5F35-BMP2), was constructed, propagated, and purified as previously described. 11, 12, 14 Control vectors included: Ad5-lacZ, an Ad5 vector containing a CMV promoterdriven b-galactosidase expression cassette in region E1; and Ad5F35-HM4, lacking a transgene cassette. Particle to plaque-forming unit (PFU) ratios were 12.5, 56, 20, and 562 for Ad5F35-BMP2, Ad5-BMP2, Ad5-lacZ, and Ad5F35-HM4, respectively. This high particle/PFU ratio is always observed with Ad5F35-HM4. Infection of A549 cells indicated no contamination of these vectors with wild-type virus (replication-competent adenovirus; RCA).
Transduction of cells with adenoviral vectors
The cells were transduced with adenoviral vectors as previously described. 11 Briefly, cells were infected at the specified multiplicity in DMEM supplemented with 2% FBS and the antibiotic-antimycotic. Virus was allowed to adsorb overnight and then the media was adjusted to 10% FBS.
In vitro identification and quantitation of BMP2 expression
For Western blot analysis, extracts were generated from cells that had been transduced with adenovirus and cultured for 3 days before lysis with 2 Â sample buffer (125 mM Tris-HCl; pH 6.8; 4% w/v sodium dodecyl sulfate (SDS); 20% glycerol; 0.05% w/v bromophenol blue; 10% v/v b-mercaptoethanol) added just prior to gel electrophoresis. A lysate prepared from approximately 5 Â 10 6 cells was subjected to electrophoresis on a single lane of an SDS-polyacrylamide gel. Purified recombinant human protein (rhBMP2; a gift from Genetics Institute, Cambridge, MA, USA) was used as a positive control for protein detection and to establish a standard curve for protein quantitation.
BMP2 was detected by Western blot with an anti-BMP2 monoclonal antibody (h3b2/17.8.1; a generous gift from Genetics Institute, Cambridge, MA, USA) as previously described. 11, 12 Proteins from four independent experiments indicated were quantified by scanning with a laser densitometer (Molecular Dynamics, Sunnyvale, CA, USA).
In vivo heterotopic bone formation assay
Animal experiments were performed in accordance with the standards of the Department of Comparative Medicine (Baylor College of Medicine), following a review and approval of the protocol by the Animal Use and Care Committee. BM-MSCs, SFs, and MRC-5 cells were transduced with 2500 viral particles per cell with experimental and control adenoviral vectors. Following viral transduction, cells were trypsinized, and cell Adenovirus BMP2-induced bone formation Z Gugala et al suspensions were created containing 5 Â 10 6 cells in 100 ml of PBS.
The experimental groups included a combination of the three cell types and the four adenoviral vectors (two animals per group and both hind limbs of each animal were injected). The transduced cell suspensions were injected into NOD/SCID mice bilaterally in the lateral region of the quadriceps muscle using a 1 ml syringe and an18 G needle. Animals were allowed food and activity ad libitum. At 2, 3, 5, 6, 7, and 14 days postinjection, animals were euthanized, the hind limbs extracted, the skin removed, and the limbs placed in neutral formalin.
Radiographic analysis
Faxitron MX2D (Faxitron X-ray Corp., Wheeling IL, USA) was used for radiographic identification of heterotopic bone formation. The exposure time was 83 s at the accelerating voltage of 31 kV. Radiographic images were taken in both projections (anteroposterior and lateral). The distance of the specimen from the radiation source resulted in four-fold magnification.
For quantitative assessment of the amount of bone formation, the surface area of bone in biplanar projections was measured and compared. The images were digitized at a resolution of 800 dpi with a standardized brightness/contrast protocol. Heterotopically formed bone was demarcated from the remaining portion of the image and its surface area was calculated using Image Toolt software package (UTHSCSA, San Antonio, TX, USA). The unit area (mm 2 ) was calibrated using an image of a metallic gauge taken simultaneously with the samples. The calculated values (mean of n¼4) were compared using a standard Student's t-test.
Histological evaluation
The specimens were fixed in neutral formalin, decalcified in EDTA, embedded in paraffin, and sectioned at a thickness of 5 mm. Sections were stained with hemotoxylin-eosin at various intervals and observed under light microscopy. The remaining sections were used for immunohistochemical analysis and were first deparaffinized in xylene and rehydrated through a graded series of ethanol. Sections were then washed with phosphate-buffered saline containing 0.05% Tween-20 (PBST), treated with Peroxide Block (Innogenex, San Ramon, CA, USA) for 15 min and then incubated for 5 min in 0.3% Triton X-100. The sections were incubated with a 1:200 dilution of a mouse monoclonal antibody (Ms Â Hu Mitochondrial (Mab 1237), Chemicon, Temecula, CA, USA) against a human mitochondrial protein that does not crossreact with mouse, 15-17 using a PowerVision Homo-Mouset IHC Kit (ImmunoVision Technologies, Daly City, CA, USA) according to the manufacturer's instructions. Sections were counterstained for 2 min with hematoxylin, washed 5 min with water, and were then dehydrated through a graded series of ethanol and cleared using NeoClear (EM Science, Gibbstown, NJ, USA). Slides were observed using a Zeiss Axiophot light microscope equipped with a SPOT RT Camera (Diagnostic Instruments, Sterling Heights, MI, USA).
Results
In vitro expression of BMP2
In agreement with our previous experiments, 11, 12 Ad5F35-BMP2-transduced BM-MSCs synthesized considerably more BMP2 in vitro than the same cells transduced with Ad5-BMP2. Consistently, all three types of cells transduced with Ad5-BMP2 demonstrated undetectable levels of BMP2 expression (Figure 1) . Additionally, none of these cells produced detectable levels of endogenous BMP2, and BMP2 was not detected in cells transduced with control adenoviral vectors (Ad5-lacZ or Ad5F35-HM4, data not shown). However, quantitative Western blot analysis using an anti-BMP2 antibody demonstrated that only cells transduced with Ad5F35-BMP2 produced amounts of BMP2 detectable in cell lysates. However, as shown in Figure 1d , A549 cells infected with 2500 particles/cell of Ad5-BMP2 expressed more BMP2 than these cells infected with the same amount Ad5F35-BMP2, indicating that the Ad5-BMP2 vector was indeed infectious. Previously, we have shown, by bioassay, that the Ad5-BMP2 vector produces BMP2 that is functional. 11 Additionally, upon transduction of human SFs, MRC-5, or hBM-MSCs with 10 000 particles/cell Ad5-BMP2, the two former cell types, but not the latter, produced levels of BMP2 that were detectable by Western blot analysis (data not shown). No significant differences were observed between the levels of BMP2 produced by transduction of BM-MSCs, SFs, or MRC-5 cells with Ad5F3-5BMP2. (Figure 1e ). BMP2 levels were assessed from the intensity of the band of recombinant BMP2 in each Western blot (Figure 1a -d, lane 1) and compared with a standard curve generated with known amounts of recombinant BMP2.
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In vivo heterotopic bone formation All animal completed the 14-day follow-up period. No complications were noted and all animals maintained unrestricted activity level.
Radiographic analysis
At 14 days, substantial amounts of heterotopic bone were formed in the muscle of the limbs injected with BMMSCs, SFs, and MRC-5 cells transduced with Ad5F35-BMP2 (Figures 2d, 3d and 4d ). The same cell populations transduced with Ad5-BMP2 induced significantly less bone or no bone at all (Figures 2b, 3b and 4b) . None of the cells transduced with the control adenoviruses produced radiologically detectable bone (Figures 2a, c,  3a, c and 4a, c) . The surface area of the heterotopic bone, as assessed from biplanar plain radiography, demonstrated no statistically significant difference (P-value range¼0.17-0.41) in the amounts of bone formed between the three cell types transduced with the same adenovirus ( Figure 5 ). However, significantly (P-value range¼0.0002-0.003) more bone was formed using each of the three cell types transduced with Ad5F35-BMP2 as compared with Ad5-BMP2.
Histological analysis
Histological evaluations corroborated the radiographic results. Significant amounts of new bone were formed when Ad5F35-BMP2 was used irrespective of the cell type. The heterotopic bone had a normal, woven appearance, and was well demarcated from the adjacent Adenovirus BMP2-induced bone formation Z Gugala et al muscle with an irregular oval shape. The new bone formed consistently in all animals that received cells transduced with Ad5F35-BMP2 (Figure 6b, d, f) . The heterotopic bone was not contiguous with the periosteum of the femur but originated from the space in between muscle fibers radiating outward and/or splitting muscle layers. Histological analysis also confirmed that the bone was formed by an endochondral process. The most extensive cartilage formation was observed using Ad5F35-BMP2-transduced MRC-5 cells (Figure 6f) . In contrast, all cell types transduced with Ad5-BMP2 produced little or no bone (Figure 6a, c, e) . As compared with the other cell types, no significant beneficial effect of using transduced BM-MSCs in terms of the extent and maturation of the heterotopic bone could be demonstrated for either low-or high BMP2-expressing cells.
In order to determine the origin of cells in the newly formed heterotopic bone, sections were analyzed using immunohistochemical staining for a human mitochondrial protein. Positive immunohistochemical identification of human cells in vivo was performed in selected of Ad5F35BMP2 were subjected to electrophoresis under denaturing conditions and BMP2 was detected using an anti-BMP2 monoclonal antibody (Genetics Institute, Cambridge, MA, USA). After electrophoresis under denaturing conditions, BMP2 was quantitated using an anti-BMP2 monoclonal antibody (Genetics Institute). A standard curve was created using rhBMP2 (nd¼not detectable). (Figure 7 , day 6, C), the heterotopic bone ( Figure 7, day 7) , nor the surrounding muscle (not shown). This indicates that the transduced human cells are not incorporated into the newly formed cartilage or bone.
Discussion
The purpose of this study was to determine if delivery of BMP2 via transduction of an osteogenic cell is necessary for bone formation, or whether the only function of the transduced cell is to deliver the BMP2. We previously demonstrated that BMP2 expression was significantly higher in BM-MSCs transduced with Ad5F35-BMP2 than with Ad5-BMP2. 12 In the present study, the in vitro assessment of BMP2 production by cells transduced with Ad5-BMP2 demonstrated undetectable levels of BMP2. The inability to transduce efficiently hBM-MSCs with Ad5-BMP2 could be because of the total absence of CAR on these cells as we have previously shown. 12 Additionally, we have used a concentration of Ad5-BMP2 yielding 2500 particles/cell to transduce hBM-MSCs and analyzed extracts from 5 Â 10 5 cells on a single lane of a Western blot. Alternatively, other researchers 1 were able to detect BMP2 by Western blot analysis after Ad5-BMP2 transduction of rat MSCs. However, considerably more cells (8 Â 10 6 versus 5 Â 10 5 cells in our study) were transduced with a higher concentration of Ad5-BMP2. Moreover, culture supernatant from all the cells was concentrated by heparin-Sepharose beads and subjected to electrophoresis on a single lane of an SDS-polyacrylamide gel to enhance the level of BMP2 detection by Western blot. As a result of these differences, comparison of these results to ours is difficult. Presumably, under similar enhanced detection conditions we would also be able to detect BMP2 in vitro after transduction of hBMMSCs with Ad5-BMP2. We have previously been able to detect BMP2 synthesis in Ad5-BMP2-transduced W20-17 cells using a cell-based assay.
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Our study also indicates that transduced human cells do not differentiate along a chondro-osseous pathway and do not incorporate into the newly formed cartilage or bone. This conclusion differs from those of several studies, 4, 8, 9 although orthotopic rather than heterotopic bone was analyzed. The fact that several cell types can be transduced and elicit bone formation also argues against Adenovirus BMP2-induced bone formation Z Gugala et al a major contribution of the transduced cells as constituents of these new tissues.
Using cells that differ only in their expression of BMP2 allows one to determine the contribution of BMP2 to bone formation and distinguish the effects of the cells used for BMP2 delivery. The results of the present study demonstrate no significant effect of the cell type in the ability to induce heterotopic bone formation following ex vivo transduction with Ad5-BMP2 or Ad5F35-BMP2. In vitro low-or high levels of BMP2 expression resulted, depending upon whether Ad5-BMP2 or Ad5F35-BMP2 was used, irrespective of the cell type. All cell types transduced with Ad5F35-BMP2 efficiently induced heterotopic bone formation compared to the same cells transduced with Ad5-BMP2. This indicates that the level of BMP2 expression is the determining factor in the efficacy of heterotopic bone formation.
The results differ from those previously reported in the literature. Musgrave et al 10 demonstrated a diverse response in a heterotopic bone formation model, depending on the cell type used for Ad5-BMP2 transduction and intramuscular implantation. Osteogenic cells that were either genetically engineered 8 or transduced 9, 18 to express BMP2 have been shown to induce orthotopic bone formation. However, in these studies the cells were delivered using a carrier. We see variations in bone formation that are dependent on the level of BMP2 secretion. However, it is difficult to compare our model with others, since we do not include a carrier for the cells.
In the present study, the transduced human cells could not be immunohistochemically identified in the heterotopic bone or surrounding muscle 14 days postinjection, suggesting that the new bone is entirely of host origin. This indicates that in our model the transduced cells do not directly participate in bone formation, but rather, by expressing adequate levels of BMP2, trigger events in the host. Indeed, use of an osteoprogenitor (BM-MSCs) demonstrated no benefit in heterotopic new bone formation as compared with other nonosteogenic cell types. The cells, once transduced with Ad-BMP2 act primarily as a source of local BMP2, regardless of their osteogenic potential. Similarly, Engstrand et al 7 have recently demonstrated that retrovirally transduced W20-17 cells, a mouse bone marrow cell line, showed significant bone formation; however, the cells were rapidly cleared even in the presence of a collagen carrier.
As stated above, the results of the present study differ from those of other studies that demonstrated the presence of the cells transduced with Ad-BMP2 in the newly formed bone. 4, 8, 9, 18 In our study, cells were injected without carrier or scaffold, whereas in all other studies collagen carriers were utilized. 4, 8, 9, 18 Presumably, the carrier immobilizes the cells, decreasing their clearance rate. Additionally, the carrier may also retain high amounts of BMP2, forcing bone formation within the carrier, which can result in juxtaposition of the transduced cells and the new bone. Another possible explanation for our findings is that our stem cells did not demonstrate osteogenic potential in vivo. However, the BM-MSCs when cultured in osteogenic media 13 can undergo osteoblastic differentiation (data not shown) as previously reported. 19 The reported osteogenic potentials of the cells used in present study vary widely. BM-MSCs have excellent osteogenic potential and can differentiate into osteoblasts. 20, 21 Human SFs, on the one hand, have been shown to be devoid of osteogenic potential. 22 However, in the recent study of Krebsbach et al 4 rat dermal fibroblasts revealed osteogenic potential when transduced with Ad5-BMP7 and subsequently subcutaneously implanted with gelatin sponges into immunocompromised mice. The new bone was formed within 1-3 weeks, and the newly formed bone was found to be a chimera composed of both human and mouse cells. MRC-5 cells (human diploid lung fibroblasts 23 ) on the other hand are not known to have intrinsic osteogenic potential. However, in the present study, the amount and nature of the heterotopic bone formed using transduced BM-MSCs did not differ from that formed using transduced MRC-5 cells or SFs, supporting the Adenovirus BMP2-induced bone formation Z Gugala et al conclusion that the cells in the present study act only to deliver BMP2.
In conclusion, we hypothesize that the function of BMP2 in induction of heterotopic bone formation is that of a trigger. The fact that no transduced cells could be identified at 6 and 7 days postinjection suggests that a sustained level of BMP2 might not be essential, for continuing formation of heterotopic bone.
These studies have significant implications for the development of an efficacious gene therapy system for induction of bone formation. The results show that the type of cell used for adenoviral transduction is not significant, providing that levels of local BMP2 expression are adequate. Therefore, the optimal target cell should be easily transduced with the adenovirus vector and available in good numbers from an atraumatic site, circumventing the need for in vitro expansion. One candidate target cell for Ad-BMP2 could be nucleated cells of the peripheral blood. We 24 and others 25 have demonstrated the suitability of Ad5F35 vectors, unlike Ad5 vectors, to transduce efficiently human hematopoietic cells.
In summary, the studies reported here suggest that the level of BMP2 expression, not the type of cell transduced, is crucial in triggering bone formation using transduced cells expressing BMP2. Furthermore, the results suggest that the mechanism of BMP2 activity in bone formation is to recruit or mobilize host cells to create an environment that is conducive to endochondral bone formation. Figure 7 Immunohistochemical staining for human mitochondrial antigens in muscle and bone in NOD/SCID mice injected with BM-MSCs transduced with Ad5F35-BMP2. Ad5F35-BMP2-infected cells were injected into the quadriceps muscle of NOD/SCID mice. At 2, 3, 5, 6, and 7 days after injection, animals were euthanized and the injected limbs were processed for histology and human cells detected with the use of Mab1237, which specifically stains human mitochondria. Day 2, Â 40; days 3, 5, 6, and 7, Â 10. Arrows indicate positive staining, C (day 6), cartilage.
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